India’s drug regulator has implemented significant reforms to accelerate innovation within the pharmaceutical industry. Approval timelines have been reduced by more than 50%, streamlining the process for new drugs and clinical trials.
Clinical trial approvals now take between 120 to 135 days, while marketing authorizations are being cleared in under 150 days. These changes reflect a broader effort to improve the ease of doing business in India.
The reforms include the removal of pre-clinical approval requirements, further simplifying the regulatory landscape. The regulator aims to foster a more efficient and innovation-friendly environment for pharmaceutical companies operating in India.
About the Author
